Moderna, Inc.

NasdaqGS:MRNA Stock Report

Market Cap: US$21.3b

Moderna Balance Sheet Health

Financial Health criteria checks 3/6

Moderna has a total shareholder equity of $8.7B and total debt of $590.0M, which brings its debt-to-equity ratio to 6.8%. Its total assets and total liabilities are $12.3B and $3.7B respectively.

Key information

6.82%

Debt to equity ratio

US$590.00m

Debt

Interest coverage ration/a
CashUS$5.80b
EquityUS$8.65b
Total liabilitiesUS$3.69b
Total assetsUS$12.34b

Recent financial health updates

No updates

Recent updates

Moderna: The Case For Staying On The Sidelines

Apr 15

Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90

Feb 17
Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Feb 02
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%

There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise

Dec 19
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 18
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and

More Downside For Moderna Before The Breakthrough

Apr 22

FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)

Mar 31

Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out

Mar 06

Moderna, Inc.: Working Hard But Competition Is Working Harder

Feb 14
User avatar

Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks

Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.

Moderna: The Good News Isn't Enough

Feb 03

Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)

Jan 10

Moderna: 2025 Contrarian Play

Dec 31

Moderna: Cutting Costs Might Not Be Enough

Dec 18

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Nov 22

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Oct 22

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Financial Position Analysis

Short Term Liabilities: MRNA's short term assets ($6.5B) exceed its short term liabilities ($2.0B).

Long Term Liabilities: MRNA's short term assets ($6.5B) exceed its long term liabilities ($1.7B).

Debt to Equity History and Analysis

Debt Level: MRNA has more cash than its total debt.

Reducing Debt: MRNA's debt to equity ratio has increased from 0% to 6.8% over the past 5 years.

Debt Coverage: MRNA's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if MRNA's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/20 07:31
End of Day Share Price 2026/04/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moderna, Inc. is covered by 46 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Huidong WangBarclays
Eliana MerleBarclays